Rare variant analysis in eczema identifies exonic variants in DUSP1, NOTCH4 and SLC9A4 by Grosche, S. et al.
ARTICLE
Rare variant analysis in eczema identifies exonic
variants in DUSP1, NOTCH4 and SLC9A4
Sarah Grosche1,2,42,45, Ingo Marenholz1,2,45, Jorge Esparza-Gordillo1,2,43,45, Aleix Arnau-Soler1,2,45,
Erola Pairo-Castineira 3,4, Franz Rüschendorf 1, Tarunveer S. Ahluwalia 5,6, Catarina Almqvist7,8,
Andreas Arnold9, Australian Asthma Genetics Consortium (AAGC)*, Hansjörg Baurecht 10,44,
Hans Bisgaard 5, Klaus Bønnelykke 5, Sara J. Brown 11, Mariona Bustamante 12, John A. Curtin13,
Adnan Custovic 14, Shyamali C. Dharmage15, Ana Esplugues16, Mario Falchi 17, Dietmar Fernandez-Orth 12,
Manuel A. R. Ferreira18, Andre Franke 19, Sascha Gerdes10, Christian Gieger 20, Hakon Hakonarson 21,
Patrick G. Holt 22, Georg Homuth23, Norbert Hubner 1, Pirro G. Hysi 17, Marjo-Riitta Jarvelin 24,25,26,
Robert Karlsson 7, Gerard H. Koppelman 27, Susanne Lau28, Manuel Lutz29, Patrik K. E. Magnusson 7,
Guy B. Marks30, Martina Müller-Nurasyid 29,31,32, Markus M. Nöthen 33, Lavinia Paternoster 34,
Craig E. Pennell 35, Annette Peters 36, Konrad Rawlik 3, Colin F. Robertson37, Elke Rodriguez 10,
Sylvain Sebert 24,25,26, Angela Simpson13, Patrick M. A. Sleiman21, Marie Standl36, Dora Stölzl10,
Konstantin Strauch29,31,32, Agnieszka Szwajda7, Albert Tenesa 3,4,38, Philip J. Thompson39,
Vilhelmina Ullemar7, Alessia Visconti 17, Judith M. Vonk 40, Carol A. Wang 35, Stephan Weidinger10,
Matthias Wielscher24, Catherine L. Worth 1, Chen-Jian Xu27,41 & Young-Ae Lee 1,2✉
Previous genome-wide association studies revealed multiple common variants involved in
eczema but the role of rare variants remains to be elucidated. Here, we investigate the role of
rare variants in eczema susceptibility. We meta-analyze 21 study populations including
20,016 eczema cases and 380,433 controls. Rare variants are imputed with high accuracy
using large population-based reference panels. We identify rare exonic variants in DUSP1,
NOTCH4, and SLC9A4 to be associated with eczema. In DUSP1 and NOTCH4 missense var-
iants are predicted to impact conserved functional domains. In addition, five novel common
variants at SATB1-AS1/KCNH8, TRIB1/LINC00861, ZBTB1, TBX21/OSBPL7, and CSF2RB are
discovered. While genes prioritized based on rare variants are significantly up-regulated in
the skin, common variants point to immune cell function. Over 20% of the single nucleotide
variant-based heritability is attributable to rare and low-frequency variants. The identified
rare/low-frequency variants located in functional protein domains point to promising targets
for novel therapeutic approaches to eczema.
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Eczema is a chronic inflammatory skin disease that is oftenassociated with immunoglobulin E (IgE)-mediated allergies.Like in other complex human diseases, there is a substantial
heritable contribution to the disease risk. In recent years, several
large genome-wide association studies (GWAS) identified a total
of 32 susceptibility loci for eczema1–9. However, despite
increasing sample sizes, the reported associations of single
nucleotide polymorphisms (SNPs) have explained only a small
fraction of the estimated heritability of eczema6,10.
It has been hypothesized that missing heritability may originate
from rare risk variants that are not well captured on SNP arrays
designed to study common variants with a minor allele frequency
(MAF) > 0.0511. Thus, the majority of low-frequency SNPs
(0.01 ≤MAF < 0.05) and rare variants (MAF < 0.01) were out of
reach in this approach. Furthermore, imputation of SNPs with
low allele frequency at high quality was unattainable since until
recently, a reference panel of sufficient size was not available.
There is increasing evidence that rare variants contribute to
disease risk not only in Mendelian diseases but also in complex
diseases. Recent studies suggested a role for low-frequency and
rare variants in a number of complex disorders including
inflammatory bowel disease, asthma, and cancer12–14. With the
Haplotype Reference Consortium panel (HRC), a new resource
has now become available including 32,488 sequenced individuals
covering almost 65,000 haplotypes15. This allows for the first time
the reliable imputation of rare variants.
In our meta-GWAS on rare variants in eczema, we uncover
disease-associated exonic variants in the genes encoding dual
specificity phosphatase 1 (DUSP1), neurogenic locus notch
homolog protein 4 (NOTCH4), and solute carrier family 9
member A4 (SLC9A4). In DUSP1 and NOTCH4, the identified
missense variants are located in functional domains. By extending
the GWAS to common variants, another five new eczema-
associated loci are detected. We estimate a contribution of over
20% for rare and low frequencies to eczema heritability.
Results
Study design and quality control. In total 21 study populations
comprising 20,016 cases and 380,433 controls were included in
our GWAS on rare variants in eczema (Supplementary Data 1).
Of them, 19 study populations with available genotypes including
10,703 cases and 30,845 controls were analyzed with RVTESTS
and combined in the rare variant set (RV set). The other two data
sets were the publicly available FINNGEN study comprising 2,663
cases and 88,760 controls and UK Biobank (UKBB) contributing
6,650 cases and 260,828 controls (Fig. 1). Our study had 80%
power to detect risk alleles with an allele frequency of 0.004 and a
risk ratio of 1.6 using an allelic model with 10% prevalence,
alpha < 1 × 10−8, and unselected controls (Supplementary
Fig. 1)16. Taking into account that rare alleles usually have a
higher impact on disease, our study was well-powered to detect
rare variants associated with eczema. The genome-wide sig-
nificance threshold was set at 1 × 10−8, as suggested previously
for GWAS analyzing variants with a MAF of 0.00117.
A total of 9,397,031 variants passed quality control in all three
data sets. There was no evidence of inflation of the test statistics
(Supplementary Fig. 2).
The combined summary statistics of 4,269,731 rare and low-
frequency variants were additionally used to perform the gene-
level association test which combines the effects of multiple
variants within a gene thus increasing power of revealing disease-
relevant genetic variants in the presence of locus heterogeneity.
Loci associated with eczema at the single SNP level. Performing
serial conditional analyses, we identified 48 independent SNPs at
38 loci to be associated with eczema at genome-wide significance
(Supplementary Data 2). Focusing only on 4,269,731 rare and
low-frequency variants, a total of 273 SNPs at 11 loci were
associated with eczema at genome-wide significance (Fig. 2,
Supplementary Data 3). The best associated rare/low-frequency
SNP at each locus is presented in Table 1. Of those, four loci were
exclusively associated with rare/low-frequency variants; at profi-
laggrin (FLG), LOC101928093/DUSP1, arrestin domain contain-
ing 1 (ARRDC1), and C-C motif chemokine receptor 7 (CCR7)/
SWI/SNF related, matrix associated, actin-dependent regulator of
chromatin, subfamily E, member 1 (SMARCE1), rare/low-fre-
quency variants were identified as independently associated lead
SNPs (Table 1, Supplementary Data 2). LOC101928093/DUSP1
has not been reported to be associated with any allergic disease
previously. Variants at ARRCD1 and CCR7/SMARCE1 were
previously identified in a study on the broader phenotype “der-
matitis or eczema” in UKBB18. Both SNPs revealed the same risk
alleles and similar effect sizes in RV set, FINNGEN, and UKBB
verifying association of the two loci with eczema. Notably, serial
conditional analysis on chromosome 1 identified the three most
frequent FLG null mutations at genome-wide significance with no
residual association in the epidermal differentiation complex
(EDC) at 1q21.3 (Supplementary Data 2).
At seven loci, Src homology 2 domain containing E (SHE), T
helper type 2 locus control region associated RNA (TH2LCRR),
natural cytotoxicity triggering receptor 3 (NCR3)/allograft inflam-
matory factor 1 (AIF1), interleukin-15 receptor subunit alpha
(IL15RA)/interleukin 2 receptor subunit alpha (IL2RA), proline rich
5 like (PRR5L), EMSY/leucine rich repeat containing 32 (LRRC32),
and regulator of telomere elongation helicase 1 (RTEL1) common
variants were more significantly associated with eczema than the
respective rare/low-frequency variant although the effect sizes were
smaller (Supplementary Data 4). Conditioning on the common
variants abolished genome-wide significance of rare/low-frequency
variants at all loci except for TH2LCRR and EMSY/LRRC32.
Conditioning on rare/low-frequency variants often revealed a
residual effect of the common variant, which may point to a larger
or exclusive impact of the common variant. Alternatively,
unidentified rare variants in linkage disequilibrium with a common
SNP may underlie the association signal.
Genome-wide investigation of the complete data set identified
48 independent SNPs at 38 loci (Supplementary Data 2). Of those
SATB1 antisense RNA 1 (SATB1-AS1)/potassium voltage-gated
channel subfamily H member 8 (KCNH8), tribbles pseudokinase
1 (TRIB1)/LINC00861, zinc finger and BTB domain containing 1
(ZBTB1), T-box transcription factor 21 (TBX21)/oxysterol
binding protein like 7 (OSBPL7), and colony stimulating factor
2 receptor subunit beta (CSF2RB) contain common eczema-
associated SNPs which were previously not identified. All loci
showed consistent effects in RV set, FINNGEN, and UKBB
(Supplementary Data 2, Supplementary Fig. 24–28). Common
variants in or near the genes encoding RUNX family transcription
factor 3 (RUNX3), TNF superfamily member 4 (TNFSF4), D-2-
hydroxyglutarate dehydrogenase (D2HGDH), DEAD-box heli-
case 6 (DDX6)/C-X-C motif chemokine receptor 5 (CXCR5), TNF
receptor associated factor 3 (TRAF3), and mitogen-activated
protein kinase kinase kinase 14 (MAP3K14)/Rho GTPase
activating protein 27 (ARHGAP27) were previously associated
in UKBB with a broad “dermatitis or eczema” phenotype18,19. We
demonstrate association of these loci with the stricter definition of
eczema (Supplementary Data 2).
Replication of eczema-susceptibility loci from previous GWAS.
In order to verify the eczema-susceptibility loci identified
in previous GWAS1–9, we looked-up in our study the
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best-associated SNP reported at each locus (Supplementary
Data 5). Using a significance threshold of P < 0.0015 (=0.05/32
loci), we replicated 24 out of 32 loci. An independent locus near
FLG on chromosome 1 (rs7512552)6 could not be confirmed, it
was eliminated after adjusting for the three identified FLG var-
iants (Supplementary Data 2, Supplementary Data 5). Six SNPs
previously identified in GWAS on Asian populations2,3 did not
replicate. However at three of these loci, on chromosomes 3, 5,
and 20, SNPs in close proximity which were not in LD with the
previously reported SNP passed the genome-wide significance
threshold (Supplementary Data 5).
Gene-level association with eczema. Limited power is the main
drawback when studying the association of individual rare
variants in complex diseases. Gene-level association tests which
combine the effects of multiple variants within a gene may
overcome this problem in the presence of locus heterogeneity. In
an explorative approach we used RV set to test different variant
selection strategies and two different gene-level association tests,
GRANVIL and SKAT which are implemented in the RVTESTS
software package20 (Supplementary Data 6). Selecting variants
based on the deleteriousness score (CADD) in combination with
the variance-component test (SKAT) performed best for the
different scenarios and identified FLG, DUSP1, and NOTCH4 to
be significantly associated with eczema in RV set.
We then performed a gene-level association test for the meta-
analysis of RV set, FINNGEN, and UKBB. For the analysis, we
used the SNP-wise Mean model of MAGMA21 which is
RV set
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Fig. 1 Study design of the meta-analysis of genome-wide association studies (meta-GWAS) on rare variants in eczema. Workflow of the meta-GWAS
on rare variants in eczema is shown. Analyzing only rare/low-frequency variants, 11 loci were detected. In the complete data set, 38 loci were detected of
which 6 were not reported to be associated with eczema or allergic disease previously. The significance threshold for the gene-level association analysis
corresponds to 13,000 genes under study (carrying at least two variants with MAF < 0.05 and a CADD score ≥ 12.37). SNP single nucleotide









TH2LCRR RTEL1-TNFRSF6B SLC9A4 
Fig. 2 Manhattan plot of the meta-GWAS results on rare variants in eczema at the single SNP level. Meta-analysis results for all variants with a minor
allele frequency < 5% are shown. For each SNP (dots), the genomic location (x-axis) and the association P value (y-axis) are indicated. The red line
corresponds to the genome-wide significance threshold of 1 × 10−8.
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equivalent to the SKAT model with the advantage of allowing the
usage of summary statistics. We included all variants with a
MAF < 0.05 and a CADD score threshold of ≥ 12.37 for
deleterious variants as suggested by Kircher et al (2014)22
capturing approximately the 5% most deleterious mutations.
13,000 genes with at least two deleterious variants were tested for
association with eczema. Genes at five loci reached genome-wide
significance at P < 3.8 × 10−6 (= 0.05/13,000; Supplementary
Data 7). All variants contributing significantly to the gene-level
association were also included in Table 1. All rare/low-frequency
variants from Table 1 revealed consistent effects in the study
populations of RV set, FINNGEN, and UKBB (Supplementary
Fig. 3–23). As identified in RV set, MAGMA confirmed FLG,
DUSP1, and NOTCH4 to be significantly associated with eczema
in the complete data set (Supplementary Data 7). In addition,
SLC9A4 and PRR5L passed the genome-wide significance
threshold.
Since within the EDC on chromosome 1 and the MHC on
chromosome 6, SNPs in multiple genes reached genome-wide
significance (Supplementary Fig. 29), we conditioned the results
on the three identified FLG variants and the two significantly
associated NOTCH4 variants from MAGMA, rs8192591 and
rs526945, and repeated the gene-level association test. All
significantly associated genes within the EDC and within the
MHC disappeared (Supplementary Fig. 29) suggesting that the
best-associated genes FLG and NOTCH4 represented the main
eczema-susceptibility genes in these regions.
Functional assessment of the rare/low-frequency eczema-
associated variants. We evaluated the potential impact of the
identified rare/low-frequency variants on protein function by
analyzing their sequence context and reviewing their annotations
in databases using the GTEx Portal23, MutationTaster24, and
HaploReg v4.125. We included the lead SNPs from the single
variant and gene-based analysis (Table 1). In addition, all SNPs in
high LD with the associated variants (r2 > 0.8) were identified and
functionally assessed (Supplementary Data 8).
New exonic variants were identified in DUSP1, NOTCH4, and
SLC9A4. In the dual specificity phosphatase 1 gene (DUSP1) at
5q35.1, the best associated low-frequency variant rs114503346 was
in high LD (D’= 0.95; r2= 0.70) with two low-frequency missense
variants, rs34471628 and rs34013988 (Table 1). Both missense
variants were in complete LD (D’= 1, r2= 1). Accordingly, their
minor alleles, rs34471628_G and rs34013988_T, are located on the
same haplotype which had a protective effect on eczema.
Conditioning on rs114503346 did not yield any further association
signal in that region (Supplementary Data 2). DUSP1 encodes a
phosphatase which specifically dephosphorylates serine and
threonine residues. DUSP1 is ubiquitously expressed with high
mRNA levels in human skin (GTEx Portal on 12/04/20)23. The
eczema-associated variants were located within regulatory regions
in a wide range of tissues including skin and blood (Supplemen-
tary Data 8). Two functional motifs were previously identified to
be important for DUSP1 function, the kinase interacting motif
which binds the respective kinases and the phosphotyrosine-
binding loop which is the active site of DUSP126,27. We used
molecular modelling to investigate whether the variants identified
in our study would affect these motifs and consequently impact
protein function (Fig. 3).
Variant rs34013988_T leads to a substitution of alanine by
threonine at residue 56 (p.Ala56Thr) and rs34471628_G changes
tyrosine to histidine at residue 187 (p.Tyr187His). Both wild-type
amino acids, Ala56 and Tyr187, are highly conserved among
vertebrates (phastCons28 scores of 1). Ala56 is located within the
kinase interacting motif of DUSP1 (Fig. 3a) which is found to be
identical in other vertebrates and in human DUSP4 which is
another member of this protein family26. Substitution of non-
polar alanine by polar threonine may alter the kinase-binding
capacity and thus affect the activity or specificity of DUSP1.
Within the amino acid sequence, Tyr187 is located distant from
the functional motifs. In the predicted 3D-structure of DUSP1,
however, it is shifted close to the phosphotyrosine-binding loop
(Fig. 3b) which is the catalytic site of DUSP1. Accordingly,
replacement of Tyr187 with histidine could affect the catalytic
activity of the protein. Histidine is frequently found in the active
site of proteins because of its distinctive property to function as
base or as acid in catalysis. Notably, His187 is located at a similar
distance from the catalytic site as Asp227 which has been shown
to contribute to the catalytic activity of DUSP1 as a general acid/
base27. In addition, we found DUSP1 expression to be
dysregulated in lesional skin of eczema patients further support-
ing a role in eczema (Supplementary Fig. 30).
While serial conditional analysis on chromosome 6 identified
three independent common SNPs (rs2844594, rs6913664 and
rs13208697) within the major histocompatibility complex (MHC)
(Supplementary Data 2), the gene-level analysis on rare variants
identified NOTCH4 as the best-associated gene in this region
(Supplementary Data 7). Two variants with high CADD score
contributed to the association with NOTCH4; rs8192591 and
rs526945 (Table 1) which were in LD with the common variants
rs6913664 and rs13208697 (Supplementary Data 4). Conditioning
on the two NOTCH4 variants eliminated genome-wide signifi-
cance of rs6913664 and rs13208697 suggesting that low-
frequency, functional variants may underlie association of
common variants at this locus. The association signal of the
third common SNP, rs2844594, remained thus representing an
independent signal.
The best-associated low-frequency variant from the single SNP
analysis in the MHC region, the intergenic variant rs28732147,
also pointed to the functional variant rs8192591 since both SNPs
were in high LD (D’= 0.92, r2= 0.53) and revealed almost
identical effect sizes (Table 1). rs8192591 is located in exon 9 of
NOTCH4 (NM_004557.4). It is a missense variant causing a
substitution of nonpolar glycine to polar serine at residue 534
within the highly conserved (phastCons score of 0.97) EGF-like
domain 13 (Table 1, Supplementary Data 8) which may affect the
domain’s calcium-binding capacity. The second variant rs526945
is located 4.5 kb upstream of NOTCH4 in a predicted promoter/
enhancer region (CADD score of 15.2, Supplementary Data 8).
Highest expression of NOTCH4 has been reported in lung,
adipose, and breast tissue, as well as in monocytes23,29.
On chromosome 2, the common SNP rs3755274 in IL18R1
which revealed the strongest association signal (Supplementary
Data 2) was in LD (D’= 0.85, r2= 0.09) with the low-frequency
missense variant rs61731289 in SLC9A4 which was identified in
the gene-level analysis (Supplementary Data 4, Supplementary
Data 7). We propose the coding variant rs61731289 (CADD score
of 15.2) changing arginine to lysine in position 640 of SLC9A4 as
potential causal allele and effector transcript at this locus. SLC9A4
is mainly expressed in stomach, at lower levels in kidney and
esophageal mucosa (GTEx Portal on 12/04/20)23.
Pathway enrichment analysis and tissue-specific gene
expression. We performed a pathway enrichment analysis for GO
terms and curated gene-sets30 and a tissue expression analysis for
the 54 tissues included in GTEx23 with MAGMA21. In the tissue-
specific gene expression analysis, we observed a significant cor-
relation between the distribution of P values of SNPs and gene
expression in small intestine, spleen, lung, whole blood, visceral
omentum, and colon (Supplementary Fig. 31–33).
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Using all GWAS SNPs, we observed a significant enrichment of
immune-related pathways involved in cytokine signaling, T-cell
differentiation and activation as well as enrichment of genes
related to the cornified cell envelope in keratinocytes (Supple-
mentary Data 9). Stratifying the results according to allele
frequency revealed that rare/low-frequency SNPs were associated
with the cornified cell envelope whereas common SNPs were
associated with immune functions (Supplementary Data 10).
Moreover, we extended the analysis to candidate genes mapped
from genome-wide significant variants, and evaluated their
enrichment among differentially expressed gene (DEG) sets as
defined for 54 different tissues. Prioritized genes from all genome-
wide significant variants were enriched in sets of up-regulated
DEGs in whole blood and skin (Supplementary Fig. 34a).
Prioritized genes from only common variants were also enriched
in sets of up-regulated DEGs in whole blood, as well as in small
intestine (Supplementary Fig. 34b). In contrast, prioritized genes
from rare/low-frequency variants were overrepresented in sets of
up-regulated DEGs in skin and esophagus mucosa (Supplemen-
tary Fig. 34c). To exclude that the results for the rare/low-
frequency variants were exclusively driven by FLG mutations, we
repeated the analysis after conditioning on the three known FLG
variants identified. This eliminated all prioritized genes from the
epidermal differentiation complex and still identified a significant
enrichment of the remaining genes in up-regulated DEGs from
skin (Supplementary Fig. 34d).
Heritability explained by rare variants. In order to quantify the
contribution of rare and low-frequency variants to the heritability
of eczema, we used an in house data set comprising 7,092
unrelated individuals (20.1% cases) with HRC-imputed geno-
types. GREML-LDMS was used to estimate heritability for 3
frequency bins including rare variants (MAF < 0.01), low-
frequency variants (0.01 < MAF < 0.05), and common variants
(MAF > 0.05) respectively. In total 5,575,243 high-quality SNPs
(imputed at r2 > 0.9) were included in the analysis. The herit-
ability explained by rare and low-frequency variants was 4.5%
and 9.1% respectively (Supplementary Data 11 and 12). They
accounted for 23.0% of the SNP-based heritability supporting a
substantial role for rare and low-frequency in eczema
susceptibility.
Discussion
We performed a meta-GWAS of 21 study populations including
20,016 cases and 380,433 controls to determine the role of rare
variants in the development of eczema. Single SNP and gene-level
analyses identified 11 loci carrying rare/low frequency variants at
genome-wide significance. Exonic variants were detected in
DUSP1, NOTCH4 and SLC9A4. In DUSP1 and NOTCH4 the
identified missense variants were predicted to impact conserved
functional domains. The analysis of common variants yielded
another five eczema-susceptibility loci not reported previously.
Over 20% of the SNP-based heritability was explained by rare and
low-frequency variants, emphasizing the importance of studying
rare variants in eczema.
In recent years, a number of studies investigated the role of rare
variants in complex diseases. They discovered single novel loci
with rare or low-frequency variants associated with ulcerative
colitis12, age-related macular degeneration31 or schizophrenia32.
For eczema, an exome-chip based analysis in a discovery set of
2,000 cases and 15,000 controls identified a single new eczema
susceptibility locus containing low-frequency variants in the
docking protein 2 gene (DOK2)33. Utilizing HRC-imputed data
allowed us to significantly increase sample size and thus the power
in our study on rare variants. Accordingly, we identified rare/low-
frequency variants at 11 loci including three genes which con-
tained amino acid-changing variants not reported previously33.
However, it is clear that much larger data sets will be required to
dissect the contribution of rare variants to complex diseases.
Current studies on quantitative rather than binary phenotypes
identified 22 and 512 rare or low-frequency variants underlying
blood pressure34 and various blood cell traits, respectively35. They
investigated up to 1.3 million study participants.
We discovered eczema-associated missense variants in DUSP1,
NOTCH4, and SLC9A4. DUSP1 variants had a protective effect in
the single variant and in the gene-level analysis. The two missense
variants rs34471628 and rs34013988 were located near active
sites. Both may alter the functional activity or specificity of
DUSP1. Target proteins which are dephosphorylated by DUSP1
are extracellular signal-regulated kinases (ERK) 1 and 2, c-Jun N-
terminal protein kinase (JNK) 1, and a kinase negative form of
mitogen-activated protein kinase (MAPK) p38α36. Dysregulated
DUSP1 expression was reported in cultured keratinocytes of
Fig. 3 DUSP1 homology model showing (a) the wild-type protein, (b) the
mutated protein. Eczema-associated variants change the amino acids (in
pink) at positions 56 (alanine, Ala, to threonine, Thr) and 187 (tyrosine, Tyr,
to histidine, His). The kinase-interacting motif (blue), the phosphotyrosine-
binding loop (green), and Asp227 (light blue) which belongs to the catalytic
site are indicated. Acid and base groups in the functional sites are marked
red and blue respectively.
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eczema patients; association of a common candidate SNP near
DUSP1 however was weak37. Interestingly, DUSP1 has been
reported to mediate the anti-inflammatory effect of corticoster-
oids which are a mainstay of eczema therapy38. Dexamethasone-
inducedDUSP1 expression repressed the ERK, JNK and p38α
MAPK pathways and reduced the expression of inflammatory
genes in human pulmonary epithelial cells39. Hence, novel
therapies directed at modifying DUSP1 function may be bene-
ficial in eczema treatment.
In the gene-level analysis focusing on rare variants with high
functional impact, NOTCH4 was the best-associated gene in the
MHC region. The identified NOTCH4 missense mutation
rs8192591 was located in the EGF-like domain 13. While the
number of EGF-like domains vary between the NOTCH1 and
NOTCH4 receptors, the first 13 EGF-like domains are highly
conserved40, with repeats 11–13 involved in ligand binding41.
NOTCH4 belongs to a family of four highly conserved trans-
membrane receptors involved in proliferation, apoptosis, and cell
fate decisions42. Expression of all NOTCH receptors and their
ligands has been demonstrated by immunostaining in human
skin sections43; NOTCH4 was expressed in the suprabasal layers
of the epidermis and it was the major NOTCH receptor in the
stratum corneum. NOTCH4 has recently been identified as a
master molecular switch in a new pathway that decreases reg-
ulatory T (Treg) cell function in chronic inflammatory
conditions44,45. Upregulation of NOTCH4 receptor Treg cells was
necessary for allergen induced airway inflammation. NOTCH4
and its downstream effector pathways were upregulated on Treg
cells of individuals with asthma and correlated with disease
severity44.
Due to the high LD across the MHC region on chromosome 6,
association signals are notoriously difficult to dissect. Con-
ditioning on the two functional NOTCH4 SNPs eliminated
genome-wide significance of two of the three independently
associated common SNPs, suggesting that rare functional variants
may underlie the common association signals at this locus.
However, an independent association signal persists in the MHC
(rs2844594), indicating that additional eczema risk variants
remain to be discovered in that region. Functional studies will be
required to confirm a role of NOTCH4 in eczema.
On chromosome 2, the identified missense variant rs61731289
pointed to SLC9A4 as the risk gene at this locus. However, con-
ditioning on the low-frequency variant yielded strong residual
association of the common variant rs3755274 demonstrating that
other genetic risk factors exist at this locus. SLC9A4 belongs to
the SLC9 family of sodium/hydrogen exchangers and is localizing
to the plasma membrane in renal, intestinal, and other epithelia46.
The eczema associated variant rs61731289 is located within the
cytoplasmic tail of SLC9A4. While this region of SLC9A4 has not
been functionally characterized, truncation studies of this domain
in SLC9A3 have revealed its involvement in regulating ion
transporter activity47. An SLC9A4 knockout mouse revealed
major histological changes in the gastric mucosa consistent with
impaired maturation and/or differentiation of gastric epithelial
cells, as well as an inflammatory infiltrate dominated by
eosinophils48. Thus SLC9A4 may play a role in epithelial integrity
and eosinophilic inflammatory responses which are also char-
acteristic of eczema49.
Of the 5 new eczema-susceptibility loci captured by common
variants, SATB1-AS1/KCNH8, TRIB1/LINC00861, and
TBX21/OSBPL7 were previously identified in a GWAS combining
diverse inflammatory diseases excluding eczema50. Involvement
of these loci in immune functions suggests that the same
mechanisms also play a role in eczema. SATB1-AS is expressed in
a wide range of tissues including the spleen, whole blood, and gut,
whereas KCNH8 encodes a potassium channel that is primarily
expressed in the nervous system23. SATB1-AS expression is
modified by mutations in SATB151. SATB1 in turn is pre-
dominantly expressed in CD4+ CD8+ lymphocytes exerting
both activating and repressive regulatory functions implicated in
autoimmunity and cancer52. The pseudokinase TRIB1 is a key
regulator of eosinophil differentiation that are important effector
cells in allergic inflammation53. Moreover, it has been shown
recently that TRIB1 restrains antiviral effector T cell function54.
Little is known about LINC00861 function. Highest expression is
found in the spleen and whole blood. Variants in TBX21 were
associated with asthma in a candidate gene study55. TBX21
encodes the Th1-specific transcription factor T-bet which is
involved in Th1/Th2 balance and suppressed atopic dermatitis-
like skin inflammation in mice56.
ZBTB1 which was previously identified in a GWAS as a
psoriasis susceptibility locus57 is a critical determinant of T cell
development. ZBTB1 knockout mice completely lacked T cells58.
The differentiation of common lymphoid progenitors of B and
NK cell lineages was also affected59.
The CSF2RB locus was associated with asthma in a previous
GWAS60. CSF2RB encodes the common beta subunit of the
interleukin 5 (IL-5), interleukin 3 (IL-3), and granulocyte-
macrophage colony-stimulating factor (GM-CSF) receptors. It
plays a critical role in the regulation of Th2 immunity and allergic
inflammation. In Csf2rb-deficient mice, allergen-induced expan-
sion and accumulation of eosinophils in the lung was abolished
and proliferation and activity of Th2 cells was reduced61.
Tissue-specific gene expression analysis and pathway enrich-
ment analysis identified tissues and gene-sets related to immune
functions and to skin development. Interestingly rare/low fre-
quency variants and their target genes exerted their effects pre-
dominantly in skin which was still evident after adjusting for the
strong genetic effect of the low-frequency variants in FLG. In
contrast, common GWAS variants pointed to pathways and tis-
sues of the immune system as supported by the reported func-
tions of the new candidate genes from the common SNP analysis.
Focusing on cutaneously expressed genes could therefore be a
promising strategy for rare variant studies in eczema.
In order to avoid cost-intensive whole-exome or whole-
genome sequencing we performed our study on HRC-imputed
data. Before this dataset was published, imputation quality of rare
variants was generally low and many rare variants were not even
detected due to the low number of sequenced haplotypes of a
population. HRC comprises the phased haplotypes of more than
32,000 sequenced individuals and allows imputation of rare
variants with high confidence15. Accordingly, the majority of
genome-wide significant low-frequency variants was imputed at
high quality (r2 > 0.8) (Supplementary Data 13). We additionally
determined the non-reference sensitivity (NRS) and non-
reference discordancy (NRD)62 for the identified coding var-
iants in an in house data set of 892 individuals whose HRC-
imputed genotypes (after genotyping with Illumina’s
HumanOmniExpressExome-8 SNP array) and whole exome
sequences were available. Genotypes correlated very well for all
coding variants (Supplementary Data 14). Even variants with an
imputation quality r2 < 0.8 (Supplementary Data 13) confirmed
association results at known eczema loci (FLG, ARRCD1,
CCR7/SMARCE1). In addition, imputed loss-of-function muta-
tions in FLG almost perfectly matched the previously reported
allele frequencies and effect sizes63. Finally, effects of the identi-
fied exonic variants in DUSP1, NOTCH4 and SLC9A4 were
homogeneous over all study populations, supporting the validity
of the HRC-imputed approach.
Our analysis of the association between FLG and eczema has
illustrated potential pitfalls of strategies for analyzing rare var-
iants on the gene-level. In contrast to the single SNP analysis,
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gene-level tests have to take into account the genetic architecture
of a locus including different effect sizes and effect directions of
variants within a gene. Both, the SNP selection strategy and the
gene-level association test had an impact on the results (Sup-
plementary Data 6). SNP selection based on the deleteriousness
score (CADD) in combination with the variance component test
(SKAT) was most powerful for the different scenarios. Likewise a
previous study on rare and low-frequency variants in eczema
focused only on missense variants in the gene-level association
test since they are more likely to have a deleterious effect33.
We restricted our analysis to variants with a MAF > 0.001. It
has been suggested that rarer mutations could play a significant
role in complex diseases. However, our power calculation indi-
cated that larger populations are required to study those variants.
In addition, sequence data would be essential for individual
mutations which are unlikely to be included in reference data sets
for imputation. Although the number of patients affected by a
specific rare mutation may be low, the pinpointed genes and
effects on the protein level could give important clues for unra-
veling pathways involved in eczema susceptibility. Our herit-
ability estimation for rare and low-frequency variants yielded a
contribution of 13.6% to the overall heritability on the observed
scale (22.2% on the liability scale). For rare variants (MAF < 0.01)
a heritability estimate of 4.5% on the observed scale (7.4% on the
liability scale) was calculated. Mucha et al. reported a heritability
estimate of 12.56% on the liability scale for rare variants included
in the exome chip which is likely due to the large proportion
(97%) of missense and other deleterious rare variants on the
chip33. Interestingly, the heritability explained by the known loci
was mainly attributable to common variants (Supplementary
Data 11 and 12) indicating that the majority of eczema-associated
rare variants remains to be discovered.
In summary, our study on rare variants in eczema identified
novel exonic variants in 3 genes and intronic or intergenic var-
iants at another 8 loci supporting the involvement of rare and
low-frequency variants in the development of eczema. The loca-
lization of the missense variants and their potential functional
impact on the newly-identified eczema-associated genes DUSP1
and NOTCH4 suggest promising targets for future therapies.
Methods
Study populations and phenotype definition. Characteristics of the study
populations are summarized in Supplementary Data 1. The majority of them had
participated in the previous genome-wide association study (GWAS) on eczema
performed by the EArly Genetics and Lifecourse Epidemiology (EAGLE)
Consortium6. Two additional studies from Sweden, CATTS, and SALTY, as well as
two large population-based studies, FINNGEN and UKBB, were included. Eczema
was defined based on a physician’s diagnosis according to standard diagnostic
criteria64,65, on a doctor’s diagnosis reported in a questionnaire, or on self-reported
disease. The phenotype characteristics of the individual study populations are
indicated in detail in Supplementary Data 1 and Supplementary Note 1. All study
populations were of European ancestry. All relevant ethical regulations were fol-
lowed and informed consent was obtained from all participants or their legal
guardians. All studies were approved by the local ethics committees (Supplemen-
tary Note 1).
Genotyping and imputation. In total, 19 study populations with individual gen-
otype data were included in “RV set”. Genotyping, quality control (QC), genotype
imputation, and association analysis were performed in each study population
separately and are described in detail in the Supplementary Note 1. In brief, after
genotyping and appropriate QC, phasing of the genotype data into haplotypes was
carried out using SHAPEIT v266. Imputation of rare variants was performed using
the Haplotype Reference Consortium Panel on imputation servers at the Michigan
University or at the Wellcome Trust Sanger Institute15. In each data set, SNPs with
poor imputation quality (r² or info score < 0.5), a MAF less than 0.001 or deviation
from Hardy-Weinberg equilibrium in controls (P < 1 × 10−12) were excluded.
Details on genotyping, QC, genotype imputation, and association analysis in
UKBB and FINNGEN are described in Supplementary Note 1.
Imputation quality of the identified exonic variants was confirmed by
comparing imputed and sequenced genotypes in an in house data set of 892
individuals whose HRC-imputed genotypes (after genotyping with Illumina’s
HumanOmniExpressExome-8 SNP array) and whole exome sequences were
available. Non-reference sensitivity (NRS) and non-reference discordancy (NRD)
were calculated (Supplementary Data 14)62.
Association analysis at the single SNP level. Individual genotype data available in
the 19 study populations of RV set allowed us to analyze them with RVTESTS20, a tool
which implements a broad set of rare variant association statistics and which was
specifically developed to study rare variants at the genome-wide scale. GWA analysis
of the imputed SNPs with eczema was carried out per study population using a score
test as implemented in the RVTESTS software20. A covariance matrix describing the
covariance between SNPs in the population was thereby generated. After association
analysis, SNPs with a minor allele count < 1 in cases or controls were excluded in each
data set. To be included in the single SNP meta-analysis, variants had to be present in
at least 3 study populations. Single-SNP meta-analysis was performed using summary
statistics of the individual study populations and a fixed-effects model as implemented
in RareMETALS2 (https://genome.sph.umich.edu/wiki/RareMETALS2), an add-on R-
package to RAREMETAL67 for the meta-analysis of rare variant association results
from binary traits. Covariance matrices were included as covariates. Subsequently,
summary data on eczema from UKBB and from FINNGEN were meta-analyzed with
the summary data of RV set by using the sample size method of METAL68 which uses
P values and effect directions, weighted according to sample size. All SNPs with data in
RV set, UKBB, and FINNGEN were included. To identify all independent association
signals at a locus, we performed serial conditional analyses with GCTA69. A ± 1 Mb-
window around each lead SNP was defined and association signals within the window
were conditioned on the lead SNP. This procedure was repeated until all genome-wide
signals at a locus were eliminated (Supplementary Data 3).
If a rare and a common variant were associated with eczema at genome-wide
significance at a specific locus, we mutually conditioned the results using GCTA69.
P values before and after conditional analysis were included in Supplementary
Data 4.
Association analysis at the gene level. In RV set different SNP selection stra-
tegies and gene-level association tests were explored. For aggregating SNPs into
gene units, 3 different selection strategies were applied. First, SNPs predicted to
severely impact protein levels (start lost, stop lost, stop gained, splice acceptor,
splice donor) by the Ensembl Variant Effect Predictor70 were combined. Secondly,
SNPs predicted to be missense SNPs were included on top of the first selection.
Thirdly, to include potentially functional SNPs located in intronic or promotor
regions of genes and to exclude coding SNPs with a predicted minor impact on
protein function, a deleteriousness score for SNPs was used. For the third strategy,
only SNPs with a PHRED score > 15 calculated by the Combined Annotation
Dependent Depletion (CADD) tool22 were combined.
Two different tests implemented in RareMETALS were applied to perform
association tests on the gene level by combining score statistics of rare variants per
gene; the Gene- or Region-based ANalysis of Variants of Intermediate and Low-
frequency (GRANVIL)71 and the SNP-set Kernel Association Test (SKAT)72.
GRANVIL averages the score statistics of individual variants per gene and has most
power if all variants have the same effect direction. SKAT is a variance component
test and remains powerful if variants with opposite effect directions are combined.
Finally, gene-level association analysis of the combined data set including
FINNGEN and UKBB was conducted with MAGMA21 which is equivalent to
SKAT with the advantage of allowing the usage of summary statistics.
Functional annotation. Linkage disequilibrium (LD) between SNPs was calculated
using the single-nucleotide polymorphism annotator with LD information from
the European population of the 1000 Genomes project phase 3v573. eQTLs for the
lead SNPs were identified using the single-nucleotide polymorphism annotator73.
eQTLs were only reported, if the queried SNP was the most significant eQTL SNP
for a gene in a relevant tissue per LD group. Information about eQTL SNPs in
relevant tissues was collected from the GTEx Consortium database version 6p23.
SNP functional annotations were predicted using the Ensembl Variant Effect
Predictor70 and HaploReg v4.125. Pathogenicity prediction was performed using
the MutationTaster24.
Homology modeling. The 3D structures of both wild-type and mutant DUSP1
were modeled using a locally installed version of I-TASSER 5.1 using standard
settings. Figures were prepared using PyMOL 2.4 (The PyMOL Molecular Graphics
System, Version 2.4, Schrödinger, LLC).
Pathway enrichment analysis and tissue expression analysis. Pathway
enrichment analysis and tissue expression analysis both were performed with
MAGMA21 via the FUMA webpage (https://fuma.ctglab.nl)74. Pathway enrichment
analysis included GO terms and curated gene-sets from the Molecular Signatures
Database (MSigDB)30. Expression profiles were from 54 tissue types from GTEx23.
To identify a potential difference between rare and common variants, we stratified
our results according to the minor allele frequency. Candidate genes were prior-
itized from genome-wide significant SNPs based on a combination of three SNP-
to-gene mapping strategies: positional mapping (physical position on the genome
within 10 kb), eQTL mapping (eQTL associations from any tissue type) and
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chromatin interaction mapping (3D chromatin interactions based on any built-in
chromatin interaction data available) using default parameters in FUMA74, except
for maximum P value of lead SNPs which was set at 1 × 10−8. Candidate genes
were prioritized from: all variants, common variants (MAF ≤ 0.05) and rare var-
iants (MAF < 0.05%; before and after conditioning on the 3 identified FLGloss-of-
function variants), respectively. We tested for tissue specificity of eczema prior-
itized genes using hypergeometric tests to evaluate its overrepresentation in sets of
differentially expressed genes (DEG; sets of genes which are more or less expressed
in a specific tissue compared to others) in 54 tissue types based on GTEx v8 RNA-
seq data.
SNP-based heritability analysis. We built an in-house sample of 8,134 indivi-
duals with available genotypes and HRC-imputed data. Using GCTA69, we iden-
tified and removed related individuals (—grm-cutoff 0.05). SNP variants with
MAF < 0.001, Hardy–Weinberg exact test < 1 × 10−12 and imputation quality
r2 < 0.9 were excluded using PLINK75. The final dataset included 7,092 unrelated
individuals (20.1% eczema cases) and 5,575,243 high-quality SNPs. Principal
Components (PCs) were calculated in GCTA. LD score was calculated for all SNPs
as the sum of LD r2 between a SNP and all the rest of SNPs within a region of
200 kb. All 5,575,242 SNPs were stratified in 4 bins based on the segment-based LD
score of the SNPs and each bin further divided in 3 bins based on allele frequency
(MAF < 0.01, 0.01 <MAF < 0.05, MAF > 0.05). Genomic Relationship Matrix
(GRM; 12 random genetic effects) were constructed from SNPs annotated to the 12
different bins. To estimate SNP-based heritability (h2SNP) we implemented a
GREML-LDMS model in GCTA that fit all 12 GRM together while adjusting by sex
and the first 10 PCs76. This method is unbiased regardless of the properties of the
underlying causal SNPs, therefore allowing us to robustly estimate h2SNP explained
by bins of SNPs at different MAF while correcting for the region-specific LD
heterogeneity across the genome76. Then, 2,663 significant variants (P < 1 × 10−8)
from the Meta-Analysis as well as all SNPs within a window of ±500 kb were
selected as significant loci and removed from the 12 bins annotated previously. 12
new GRM were constructed from these 12 bins of which a total of 82,621 SNPs
were excluded. Estimations of h2SNP fitting components with and without the
significant loci were compared to assess the h2SNP explained by significant loci
identified in our meta-analysis. The estimates of variance explained on the
observed scale were transformed to that on the underlying scale considering a
population prevalence of 10%.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
Summary statistics of the meta-analysis which were generated in this study have been
deposited in the GWAS Catalog (https://www.ebi.ac.uk/gwas/home) under study
accession GCST90044763.
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